Medication info
Sitadual XR Extended-Release Tablet 50/500 mg (Sitagliptin Hydrate, Metformin Hydrochloride)

Sitadual XR Extended-Release Tablet 50/500 mg (Sitagliptin Hydrate, Metformin Hydrochloride)

Prescription medicationTabletOral
Ingredient · strength
Sitagliptin Hydrochloride Hydrate›56.69mg / 1 tabletMetformin Hydrochloride›500mg / 1 tablet
Manufacturer / importer
Hyundai Pharmaceutical Co., Ltd.
Appearance
Light blue, oval-shaped, bi-convex extended-release film-coated tablets
Packaging
Bottle - 100 tablets/bottle, bottle - 30 tablets/bottle
Approval status
Active

MFDS item code 202300584 · Approved 2023.02.17 · Insurance code 642004990

Summary

Main use
Improvement of glycemic control in type 2 diabetes mellitus
Who takes it
Adults
Adult dose
When used as part of antidiabetic therapy, the dose of this drug should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily dose of each component: sitagliptin 100 mg and metformin 2000 mg. This drug should be taken once daily with a meal, preferably in the evening, and the dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. To maintain its extended-release properties, this drug must be swallowed whole and must not be split, crushed, ground, or chewed. Take 1 tablet of this drug 100/1000 mg extended-release tablet once daily. Patients taking this drug 50/500 mg extended-release tablet or 50/1000 mg extended-release tablet should take 2 tablets together once daily. 1. Patients not currently receiving metformin treatment: For patients with no previous experience of diabetes drug treatment whose blood glucose cannot be adequately controlled with monotherapy, or for whom adequate blood glucose control cannot be achieved with sitagliptin monotherapy, the initial total daily dose of this drug is sitagliptin 100 mg and metformin 1000 mg. If adequate blood glucose control cannot be achieved with the initial dose, the dose may be increased gradually up to the maximum recommended daily dose of metformin, 2000 mg, to reduce gastrointestinal adverse reactions caused by metformin. 2. Patients receiving metformin treatment: - The recommended initial total daily dose of this drug for patients whose blood glucose cannot be adequately controlled with metformin monotherapy is sitagliptin 100 mg and the patient's current dose of metformin. - Patients switching from combination therapy with sitagliptin and metformin to this drug may start at their current doses of sitagliptin and metformin. - Patients who were taking immediate-release tablets at a dose of 850 mg or 1000 mg twice daily as their current metformin dose may start with this drug 50/1000 mg extended-release tablet at a dose of 2 tablets once daily. 3. Patients whose blood glucose cannot be adequately controlled with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial total daily dose of this drug is sitagliptin 100 mg, and the initial dose of metformin should be determined based on the patient's blood glucose level and current dose. The dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. When administered in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin. Patients with renal impairment This drug may be used in patients with moderate renal impairment stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2) who have no other symptoms that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment should not be initiated with this drug because the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 1000 mg daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this drug should be discontinued immediately.

Ingredients

Manufacturer
Hyundai Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in type 2 diabetes mellitus

View approved original text

This medication is used in conjunction with diet and exercise therapy for patients with type 2 diabetes to help control blood sugar levels. The two active ingredients, sitagliptin and metformin, work together to effectively lower and regulate blood sugar levels. This allows for more efficient management of blood sugar and may contribute to the prevention of complications related to diabetes. Therefore, consistent use along with lifestyle improvements will greatly aid in blood sugar control.

How to take

Adult dose

When used as part of antidiabetic therapy, the dose of this drug should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily dose of each component: sitagliptin 100 mg and metformin 2000 mg. This drug should be taken once daily with a meal, preferably in the evening, and the dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. To maintain its extended-release properties, this drug must be swallowed whole and must not be split, crushed, ground, or chewed. Take 1 tablet of this drug 100/1000 mg extended-release tablet once daily. Patients taking this drug 50/500 mg extended-release tablet or 50/1000 mg extended-release tablet should take 2 tablets together once daily. 1. Patients not currently receiving metformin treatment: For patients with no previous experience of diabetes drug treatment whose blood glucose cannot be adequately controlled with monotherapy, or for whom adequate blood glucose control cannot be achieved with sitagliptin monotherapy, the initial total daily dose of this drug is sitagliptin 100 mg and metformin 1000 mg. If adequate blood glucose control cannot be achieved with the initial dose, the dose may be increased gradually up to the maximum recommended daily dose of metformin, 2000 mg, to reduce gastrointestinal adverse reactions caused by metformin. 2. Patients receiving metformin treatment: - The recommended initial total daily dose of this drug for patients whose blood glucose cannot be adequately controlled with metformin monotherapy is sitagliptin 100 mg and the patient's current dose of metformin. - Patients switching from combination therapy with sitagliptin and metformin to this drug may start at their current doses of sitagliptin and metformin. - Patients who were taking immediate-release tablets at a dose of 850 mg or 1000 mg twice daily as their current metformin dose may start with this drug 50/1000 mg extended-release tablet at a dose of 2 tablets once daily. 3. Patients whose blood glucose cannot be adequately controlled with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial total daily dose of this drug is sitagliptin 100 mg, and the initial dose of metformin should be determined based on the patient's blood glucose level and current dose. The dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. When administered in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin. Patients with renal impairment This drug may be used in patients with moderate renal impairment stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2) who have no other symptoms that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment should not be initiated with this drug because the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 1000 mg daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this drug should be discontinued immediately.

Precautions

This medication contains two ingredients for the treatment of diabetes. The first ingredient helps in regulating blood sugar, while the second ingredient is effective at lowering blood sugar. The most important point while taking this medication is to be cautious of allergic reactions. Rarely, severe allergic reactions or skin conditions may occur, so if symptoms such as skin rash, itching, or difficulty breathing arise, stop taking the medication immediately and consult a physician. Additionally, there is a risk of pancreatitis, which involves inflammation of the pancreas, so if symptoms such as abdominal pain, vomiting, or fever occur, inform medical personnel immediately. It is also recommended to avoid this medication in patients with poor kidney function, dehydration, serious infections, or heart disease for safety. Patients with reduced kidney function should consult a physician before taking this medication and undergo regular kidney function tests. Pregnant or nursing women should not take this medication, and safety and efficacy have not been established in children under 18 years of age. During treatment, be mindful that irregular meals, excessive exercise, or other medications may cause hypoglycemia. Particularly, when taken with insulin or sulfonylureas, the risk of hypoglycemia may increase, so it is important to monitor blood sugar levels frequently. Alcohol consumption should be avoided while taking this medication, as acute alcohol intoxication or impaired liver function may cause severe side effects such as lactic acidosis. Stop taking this medication temporarily if undergoing surgery or tests that use contrast agents, and the decision to resume should be based on kidney function test results. This medication may decrease vitamin B12 levels, so if taking it long-term, it is advisable to check vitamin B12 status regularly through blood tests. Finally, in the case of an overdose, immediately seek medical attention for appropriate treatment, as some ingredients can be removed by dialysis. As this medication has various precautions and side effects, it is essential to consult with a physician or pharmacist before taking it and follow their instructions.

Side effects

  • Anaphylaxis
  • angioedema
  • Stevens-Johnson syndrome
  • acute pancreatitis
  • lactic acidosis
  • hypoglycemia
  • diarrhea
  • upper respiratory tract infection
  • headache
  • nausea
Show 26 more
  • vomiting
  • abdominal pain
  • rhinitis
  • constipation
  • severe arthralgia with disability
  • bullous pemphigoid
  • myalgia
  • limb pain
  • back pain
  • interstitial lung disease
  • pruritus
  • thrombocytopenia
  • rhabdomyolysis
  • rash
  • urticaria
  • cutaneous vasculitis
  • elevated liver enzymes
  • acute renal failure
  • hypoglycemia
  • hypoglycemic symptoms
  • adverse reactions to hypoglycemia
  • severe hypoglycemia
  • decreased vitamin B12
  • severe arthralgia
  • bullous pemphigoid
  • hypoglycemic symptoms

Not everyone experiences these, and they can vary from person to person.

Storage

Store this medication in a sealed container as it is sensitive to air and moisture. It is important to maintain a storage temperature between 1 to 30 degrees Celsius. This will help preserve the medication's effectiveness and safety over time.

Appearance and packaging

Appearance

Light blue, oval-shaped, bi-convex extended-release film-coated tablets

Package unit

Bottle - 100 tablets/bottle, bottle - 30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.